Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer
NCT06922539
This study is recruiting at 2 US sites in 2 states, according to its ClinicalTrials.gov record last updated .
Summary
This study evaluates a fenretinide phospholipid suspension for the treatment of small cell lung cancer (SCLC).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Small Cell Lung Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- SciTech Development, Inc.
- Last updated on ClinicalTrials.gov
- August 19, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- University of Southern California · Los Angeles, CA
Michigan · 1
- Henry Ford Cancer Institute · Detroit, MI
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.